Participants
HEPATITIS A
From 30 July to 25 August 2021, a total of 355 participants aged 18 years or older were selected, 270 participants were enrolled and underwent randomization. One hundred and eighty participants were assigned to the CoronaVac group (including 90 adults aged 18 to 59 years and 90 adults aged 60 years or older), and 90 participants were in the control group (including 45 adults aged 18 to 59 years and 45 adults aged 60 years or older). Of these participants, 269 were vaccinated with the first dose of CoronaVac or one dose of PPV23 on day 0, and 249 were vaccinated with the second dose of CoronaVac or a dose of the hepatitis A vaccine (Study flow of the trial.